Meltzer PC, Butler D, Deschamps JR, Madras BK. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. PMID16480278DOI: 10.1021/jm050797a
Paillet-Loilier M, Cesbron A, Le Boisselier R, Bourgine J, Debruyne D. Emerging drugs of abuse: current perspectives on substituted cathinones. Subst Abuse Rehabil. 2014; 5: 37-52. PMID24966713DOI: 10.2147/SAR.S37257
Simmons SJ, Leyrer-Jackson JM, Oliver CF, Hicks C, Muschamp JW, Rawls SM, Olive MF. DARK Classics in Chemical Neuroscience: Cathinone-Derived Psychostimulants. ACS Chem. Neurosci. 2018; 9(10): 2379-2394. PMID29714473DOI: 10.1021/acschemneuro.8b00147
Beck O, Bäckberg M, Signell P, Helander A. Intoxications in the STRIDA project involving a panorama of psychostimulant pyrovalerone derivatives, MDPV copycats. Clin Toxicol (Phila). 2018 Apr;56(4):256-263. PMID28895757DOI: 10.1080/15563650.2017.1370097
Majchrzak M, Celiński R, Kuś P, Kowalska T, Sajewicz M. The newest cathinone derivatives as designer drugs: an analytical and toxicological review. Forensic Toxicol. 2018;36(1):33-50. PMID29367861DOI: 10.1007/s11419-017-0385-6
Davis S, Rands-Trevor K, Boyd S, Edirisinghe M. The characterisation of two halogenated cathinone analogues: 3,5-difluoromethcathinone and 3,5-dichloromethcathinone. Forensic Sci Int. 2012 Apr 10;217(1-3):139-45. PMID22088945DOI: 10.1016/j.forsciint.2011.10.042
Błażewicz, A., Bednarek, E., Popławska, M. et al. Identification and structural characterization of synthetic cathinones: N-propylcathinone, 2,4-dimethylmethcathinone, 2,4-dimethylethcathinone, 2,4-dimethyl-α-pyrrolidinopropiophenone, 4-bromo-α-pyrrolidinopropiophenone, 1-(2,3-dihydro-1H-inden-5-yl)-2-(pyrrolidin-1-yl)hexan-1-one and 2,4-dimethylisocathinone. Forensic Toxicol 2019; 37: 288-307. DOI: 10.1007/s11419-018-00463-w
Meltzer PC, Butler D, Deschamps JR, Madras BK. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. PMID16480278DOI: 10.1021/jm050797a
Paillet-Loilier M, Cesbron A, Le Boisselier R, Bourgine J, Debruyne D. Emerging drugs of abuse: current perspectives on substituted cathinones. Subst Abuse Rehabil. 2014; 5: 37-52. PMID24966713DOI: 10.2147/SAR.S37257
Simmons SJ, Leyrer-Jackson JM, Oliver CF, Hicks C, Muschamp JW, Rawls SM, Olive MF. DARK Classics in Chemical Neuroscience: Cathinone-Derived Psychostimulants. ACS Chem. Neurosci. 2018; 9(10): 2379-2394. PMID29714473DOI: 10.1021/acschemneuro.8b00147
Beck O, Bäckberg M, Signell P, Helander A. Intoxications in the STRIDA project involving a panorama of psychostimulant pyrovalerone derivatives, MDPV copycats. Clin Toxicol (Phila). 2018 Apr;56(4):256-263. PMID28895757DOI: 10.1080/15563650.2017.1370097
Majchrzak M, Celiński R, Kuś P, Kowalska T, Sajewicz M. The newest cathinone derivatives as designer drugs: an analytical and toxicological review. Forensic Toxicol. 2018;36(1):33-50. PMID29367861DOI: 10.1007/s11419-017-0385-6
Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit. 2004 Apr;26(2):127-31. PMID15228152
Davis S, Rands-Trevor K, Boyd S, Edirisinghe M. The characterisation of two halogenated cathinone analogues: 3,5-difluoromethcathinone and 3,5-dichloromethcathinone. Forensic Sci Int. 2012 Apr 10;217(1-3):139-45. PMID22088945DOI: 10.1016/j.forsciint.2011.10.042
Advisory Council on the Misuse of Drugs (UK). Consideration of the cathinones. 31 March 2010., su homeoffice.gov.uk. URL consultato il 17 luglio 2011. (archiviato dall'url originale il 22 settembre 2011).
